Adamas Pharma Revenue, Profits - ADMS Annual Income Statement

Add to My Stocks
$27.1 $0.65 (2.46%) ADMS stock closing price Mar 16, 2018 (Closing)

Financial statements provide us with a way to gain insights and undertake the fundamental analysis of a company. Checking Adamas Pharma stock price alone is not sufficient. In the income statement, an investor can look at important parameters like revenue or sales, gross profits, net profits, and EPS basic to gain deeper insights. When compared with the corresponding income statement from the past, the latest income statement shows how revenue has decreased from 1.91M to - and how operating and non operating activities have impacted the ADMS stock. Revenue for year 2016 is $- and has decreased from $1.91M year on year as is evident when you compare the latest figures in the latest Adamas Pharma profit and loss statement with those of the prior corresponding period. Also see Adamas Pharma assets and Adamas Pharma free cash flow for a complete valuation of ADMS stock.

View revenue and profit details for latest and last 10 financial years.
show more
Fiscal year is Jan - Dec20162015201420132012
Adamas Pharma Revenues or Net Sales
Cost Of Goods Sold (COGS)-----
Adamas Pharma Gross Profit
Research & Development Expense31.23M35.89M21.86M7.41M9.19M
Selling General & Admin Expense30.32M23.45M15.47M6.66M8.33M
Income Before Depreciation Depletion Amortization-60.98M-57.43M18.51M57.01M19.94M
Depreciation Depletion Amortization-----
Non Operating Income---0.91M-4.81M-1.53M
Interest Expense-----
Adamas Pharma Pretax Income
Provision for Income Taxes-0.11M-5.27M7.37M1.19M-
Investment Gains Losses-----
Other Income-----
Income Before Extraordinaries & Disc Operations-60.05M-51.8M10.22M50.92M17.73M
Extraordinary Items & Discontinued Operations-----
Adamas Pharma Profit/ Loss (Net Income)
Average Shares used to compute Diluted EPS21.71M18.11M17.11M15.8M-
Average Shares used to compute Basic EPS21.71M18.11M14.84M13.42M-
Income Before Nonrecurring Items-60.06M-51.8M10.22M33.07M-
Income from Nonrecurring Items-----
Adamas Pharma Earnings Per Share Basic Net
Adamas Pharma Earnings Per Share Diluted Net
EPS Diluted Before Nonrecurring Items-2.77-2.860.533.51-
Preferred Dividends Acc Pd-----
Dividends Common-----
Dividend Per Share Common0.
All figures in USD. M: Millions of USD, B: Billions of USD.

Before investing one should read a report on Adamas Pharma stock analysis. It helps to look at the following income statement items:

  • Topline: A growing topline, as seen from the Adamas Pharma revenue chart, as isn't the case with Adamas Pharma indicates a sagging business. One needs to compare the YoY topline or sales growth of ADMS stock with its peers like CBAY stock and VYGR stock to see if the growth compares well with what can be expected from a company in that industry.
  • Bottom line: The bottomline or the net income figure is arrived at by deducting all expenses from the topline which in this case is $-60.05M for ADMS stock. An improving bottomline implies that the company is growing its profits.

The income statement is also called the profit and loss statement. Apart from the ADMS income statement, one can check the Adamas Pharma historical stock prices to check how the price has moved with time.

Adamas Pharma Income Statement - Key Financial Ratios

PS Ratio (price sales ratio)
Dividend Yield